Paladin Labs JTSX: PLB

Nuvo sells additional Canadian Pennsaid(R) rights to Paladin subsidiary

· Issued by Paladin Labs J via CNW
MARKHAM, ON, Jan. 17 /CNW/ - Nuvo Research Inc. (TSX: NRI) and Paladin
Labs Inc. (TSX: PLB) today jointly announced that they have entered into an
agreement which expands their relationship with respect to the sale and
marketing of Pennsaid(R) in Canada. In August 2005, Squire Pharmaceuticals
Inc. (formerly Dimethaid Health Care Ltd.) was acquired by Paladin from Nuvo.
The terms of this expanded agreement include Squire making an up-front
payment, providing on-going royalties on the sale of Pennsaid(R) and making an
investment of $500,000 in Nuvo through a three-year debenture convertible into
Nuvo shares at a conversion price of $0.456, which is based on the ten-day
average closing price.
"We are pleased to broaden our relationship with Paladin, a company with
a proven ability to successfully build leading brands in Canada," said
John London, Nuvo's Vice Chairman. "This transaction provides non-dilutive
funding for our operations, including our drug development program, to     
mid-2006 when we plan to submit our amended New Drug Application (NDA) for
Pennsaid(R) to the U.S. Food and Drug Administration (FDA)."
"Clinical data indicates that Pennsaid(R) is as effective as oral
diclofenac, considered the "gold standard" treatment for osteoarthritis, but
with significantly fewer adverse events. Providing safer and effective
alternatives like Pennsaid(R) to some of the four million Canadians living
with osteoarthritis, furthers Paladin's goal of improving the lives of
Canadians," said Jonathan Ross Goodman, President and CEO of Paladin. "We are
excited that we have been able to expand our rights to Pennsaid(R) and our
relationship with Nuvo."

About Pennsaid(R)
Pennsaid(R) is a topical non-steroidal anti-inflammatory (NSAID) used for
the treatment of osteoarthritis and is currently approved for sale in Canada
and several European countries. Pennsaid(R) allows the diclofenac solution to
be delivered to a specific site via the surface of the skin and thus avoids
complications associated with systemic delivery. According to published
clinical trials, Pennsaid(R) is as effective as the maximum daily dose of
comparable oral medication at relieving pain and stiffness associated with
osteoarthritis of the knee, as well as improving overall well-being. There is
currently no topical NSAID product approved in the U.S., which represents a
$6.5 billion osteoarthritis pain relief market.

About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a leading
specialty pharmaceutical company focused on developing, acquiring or        
in-licensing innovative pharmaceutical products for the Canadian market. With
this strategy, a focused national sales team and proven marketing expertise,
Paladin has evolved into one of Canada's leading specialty pharmaceutical
companies. Paladin's shares trade on the Toronto Stock Exchange under the
symbol PLB. For more information about Paladin, please visit the Paladin web
site at www.paladinlabs.com.

About Nuvo Research Inc.
Nuvo is focused on developing innovative site-specific therapeutics that
are delivered topically using the Company's skin-penetrating technologies.
Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory
(NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its
skin-penetrating technologies to create a portfolio of transdermal products
targeting a variety of indications.
Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company
headquartered in Markham, Ontario, with manufacturing facilities in Varennes,
QuDebec and Wanzleben, Germany. For more information, please visit
www.nuvoresearch.com.

This release may contain forward-looking statements, subject to risks and
uncertainties beyond management's control. Actual results could differ
materially from those expressed here. Risk factors are discussed in the
Company's annual information form filed with the securities commissions in
each of the provinces of Canada. The Company undertakes no obligation to
revise forward-looking statements in light of future events.


Paladin Labs J on 6ix

Earlier from Paladin Labs J

Later from Paladin Labs J

All Paladin Labs J news releases